Ana Cristina Andreazza


Canada Research Chair in Molecular Pharmacology of Mood Disorders

Tier 2 - 2017-11-01
Renewed: 2021-06-01
University of Toronto
Canadian Institutes of Health Research


ana.andreazza@utoronto.ca

Research involves


Focusing on the brain and its redox biology, with particular reference to the role of mitochondrial dysfunction and the impact of impact of redox modification to lipids, protein and DNA on illness progression in major psychiatric disorders.

Research relevance


To find affordable, easy-to-use biological markers to prevent the progression of mood disorders, help develop new and effective treatments and reduce the stigma surrounding these conditions.

Research summary


One in 10 Canadian adults suffers from a mood or anxiety disorder, such as bipolar disorder, major depressive disorder and schizophrenia. Dr. Ana Andreazza, Canada Research Chair in Molecular Pharmacology of Mood Disorders, aims to better understand the mechanisms that underlie these illnesses.

She and her research team are trying to determine the role that mitochondrial dysfunction plays in neurotransmission and psychiatric disorders. (Mitochondria are tiny structures inside cells that create energy.) To untangle this complex problem, Andreazza and her team are studying post-mortem brain samples from patients who suffered from bipolar disorder to determine the role that mitochondrial dysfunction and genetics play in neurotransmission. They are also identifying peripheral biomarkers that reflect the central causes of bipolar disorder. Ultimately, their findings could lead to new treatments for mood disorders.